EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database

Wangyu Ye, Yuan Ding, Meng Li, Zhihua Tian, Shaoli Wang, Zhen Liu

Frontiers in Pharmacology · 12.09.2024 · 15

DOI: 10.3389/fphar.2024.1452300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.09.2024. Verfasst von Wangyu Ye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sulfasalazine is a widely used anti-inflammatory medication for treating autoimmune disorders such as ulcerative colitis (UC), Crohn’s disease, and rheumatoid arthritis. However, its safety profile has not been systematically evaluated in real-world settings. By analyzing the FDA Adverse Event Reporting System (FAERS) database, we identified risk signals associated with adverse reactions to sulfasalazine, offering valuable insights for clinical decision-making and risk management.

Methods

Reports of adverse events (AEs) associated with sulfasalazine, covering the period from Q1 2004 to Q4 2023, were extracted from the FAERS database. Detailed case information was aggregated to assess demographic characteristics. The associations between sulfasalazine and adverse events were evaluated using the Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayes Geometric Mean (EBGM).

Results

We extracted 7,156 adverse event reports from the FAERS database where sulfasalazine was identified as the “Primary Suspect (PS)” drug. Using disproportionality analysis, we identified 101 preferred terms (PT) related to sulfasalazine across 24 organ systems. Notable adverse reactions consistent with the drug’s labeling were observed, including Stevens-Johnson syndrome, agranulocytosis, eosinophilic pneumonia, and crystalluria. Additionally, novel positive signals not previously documented in the drug label were identified, including acute febrile neutrophilic dermatosis, aseptic meningitis, glomerulonephritis, and hepatosplenic T-cell lymphoma.

Conclusion

Most of the adverse reaction findings in this study are consistent with previous clinical research, and we have also identified new potential AEs associated with sulfasalazine. These findings provide valuable insights for the safety monitoring and clinical application of sulfasalazine.

Schlagwörter

Stichwörter der Autor:innen

FDA adverse events reporting systemadverse drug reactionadverse eventpharmacovigilancesulfasalazine

Autor:innen und Institutionen

  • Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Zitieren

APA

Ye, W., Ding, Y., Li, M., Tian, Z., Wang, S., & Liu, Z. (2024). Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1452300

Vancouver

Ye W, Ding Y, Li M, Tian Z, Wang S, Liu Z. Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1452300

BibTeX
@article{Ye2024,
  author = {Ye, Wangyu and Ding, Yuan and Li, Meng and Tian, Zhihua and Wang, Shaoli and Liu, Zhen},
  title = {Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1452300}
}
Kostenlos starten →